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Abstract
Background: Autophagy is a cellular pathway that regulates transportation of cytoplasmic macromolecules and
organelles to lysosomes for degradation. Autophagy is involved in both tumorigenesis and tumour suppression.
Here we investigated the potential prognostic value of the autophagy-related proteins Beclin-1, p62, LC3 and
uncoordinated (UNC) 51-like kinase 1 (ULK1) in a cohort of colorectal cancer (CRC) specimens.
Methods: In this study, we analysed the immunoexpression of the autophagy-related proteins p62, LC3, Beclin-1
and ULK1 in 127 CRC patients with known KRAS mutational status and detailed clinical follow-up.
Results: Survival analysis of p62 staining showed a significant correlation of cytoplasmic (not nuclear) p62 expression
with a favourable tumour-specific overall survival (OS). The prognostic power of cytoplasmic p62 was found in the
KRAS-mutated subgroup but was lost in the KRAS wildtype subgroup. Survival analysis of Beclin-1 staining did not
show an association with OS in the complete cohort. LC3 overexpression demonstrated a slight, though not significant,
association with decreased OS. Upon stratifying cases by KRAS mutational status, nuclear (not cytoplasmic) Beclin-1
staining was associated with a significantly decreased OS in the KRAS-mutated subgroup but not in the KRAS wildtype
CRCs. In addition, LC3 overexpression was significantly associated with decreased OS in the KRAS-mutated CRC
subgroup. ULK1 expression was not correlated to survival.
Conclusions: Immunohistochemical analyses of LC3, p62 and Beclin-1 may constitute promising novel prognostic
markers in CRC, especially in KRAS-mutated CRCs. This strategy might help in identifying high-risk patients who would
benefit from autophagy-related anticancer drugs.
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Background
Macroautophagy, herein referred to as autophagy, is a
process that allows cells to deliver intracellular proteins,
lipids and organelles to lysosomes where degradation
can take place [1]. After autophagic degradation, the
intracellular material is removed from the lysosomal
compartment and recycling occurs in the cytoplasm [2].
The impact of autophagy on cellular physiology varies
and depends upon the circumstances of the affected cell.
The process of autophagy is also involved in tumorigen-
esis and can be both tumour promoting as well as tumour
suppressing. Tumour-suppressive effects are achieved by
degradation of oncogenic protein substrates, toxic pro-
teins and defective organelles. However, autophagy-related
intracellular recycling of substrates necessary for mito-
chondrial activity exerts a tumour-promoting effect in
cancer cells. Autophagy can also function as a cancer cell
survival pathway. Several studies have shown that autoph-
agy is upregulated in RAS-driven cancers [3] and is espe-
cially induced in cancer areas with hypoxic conditions,
where it supports tumour cell survival [4].
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LC3, p62, Beclin-1 and uncoordinated (UNC) 51-like
kinase 1 (ULK1) are central autophagy-related proteins in-
volved in the autophagy flux. LC3 (microtubule-associated
protein 1 light chain 3) is a well-established marker of au-
tophagy activity in cancer cells [5]. LC3 is a mammalian
homolog of the yeast ATG8 protein, a ubiquitin-like pro-
tein that becomes lipidated and tightly associated with
autophagosomal membranes [6]. The hallmark of autop-
hagosome formation is characterized by the insertion of
LC3 II (isoform II of light chain) within the inner and
outer layers of the vesicle. Measurement of LC3 ex-
pression by immunohistochemistry is a frequently used
method to reliably quantify autophagosome formation [7].
p62 is an adaptor protein with several binding motifs
and functions in assembling protein complexes [8]. p62
is involved in several important signalling pathways such
as the NF-kB pathway [9]. In addition, p62 functions in
the regulation of apoptosis via activation of polyubiquiti-
nated caspase 8 [10] and influences the oxidative stress
response, which is regulated by the Keap1-Nrf2 system.
Under oxidative stress, p62 binds to Keap, which in turn
blocks Nrf2 degradation, leading to increased expression
of cytoprotective Nrf2 target genes.
Beclin-1 is an autophagy-specific protein that regulates
autophagosome formation [11]. Until recently, the BECN1
gene that encodes the Beclin-1 protein was proposed to
function as a tumour suppressor gene. However, current
studies have revealed no evidence for BECN1 mutation or
loss in cancers other than breast and ovarian cancers [12].
The allelic loss of BECN1 in breast and ovarian cancer
seems to not be a driver mutation, but a passenger muta-
tion along with BRCA1 mutation due to the proximity of
BECN1 to BRCA1. Data from the Cancer Genome Atlas
Research Network, accessible via the cBioPortal for Can-
cer Genomics, show that only 2.5 % of colorectal cancers
(CRCs) show genetic alterations of the BECN1 gene
[13, 14]. According to the cBIOPortal data, the p62
gene is altered in 1.5 % of CRC and the LC3 gene is
altered in up to 14 %.
Beclin-1 interacts with several binding partners and
can both induce and suppress the autophagy pathway.
Interaction with PI3K can lead to upregulation of au-
tophagy while interaction with Bcl-2 can result in inhib-
ition of autophagy [15]. While Beclin-1 was thought to
localize mainly in the cytosolic department, several studies
demonstrated both nuclear and cytoplasmic localization
of Beclin-1. Indeed, in a study of a cohort of CRCs, nearly
half of the cancers exhibited a significant nuclear Beclin-1
staining pattern [16].
ULK1 is a serine/threonine kinase which is essential
for autophagy and is involved in early autophagosome
formation. Under nutrient deprivation, ULK1 is activated
by the activated AMP-activated protein kinase (AMPK)
and induces initiation of autophagy [17].
In vitro studies demonstrated that treatment of tumour
cell lines with autophagy inhibitors such as chloroquine
increases chemotherapy-induced cell death, thus establish-
ing autophagy as a promising novel therapeutic target
[18–20]. Whether key autophagy proteins may predict
chemoresistance in CRC is not known. Here we investi-
gated the potential prognostic value of the autophagy-
related proteins Beclin-1, p62, LC3 and ULK1 in a cohort
of CRC specimens with a focus on patients with an un-
favourable outcome due to UICC stage III/IV CRC treated
with chemotherapy and/or KRAS-mutated CRCs.
Methods
Patients
This study comprised 127 consecutive CRC patients (66
males, 61 females) who underwent surgery from 1996 to
1998 according to the recommendations of the German So-
ciety of Surgery and who did not receive any neoadjuvant
treatment. Total/partial mesorectal excision was not per-
formed at this time. Detailed and complete clinical records
and follow-up data were available in all cases. The mini-
mum follow-up period for patients still alive was 60 months.
Surgical specimens were fixed in formalin and routinely
processed. Tumours were classified according to the TNM
System (6th edition). Patients with UICC stages III and IV
CRC received a standardized 5-fluorouracil (5-FU)-based
chemotherapy in the adjuvant setting. According to the rec-
ommendations of the German Surgical Oncology Working
group (CAO), patients with stage I and II colorectal carcin-
oma were not advised to any adjuvant treatment. Approxi-
mately 63 % of the tumours were located at the colon and
37 % were located at the rectum. Detailed information on
grading, lymph node status, T stage and distant metastasis
for all cases was available. Informed consent was obtained
from every patient, and the study protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki.
Tissue microarray construction
Multi-tissue blocks of previous studies [21] were used for
the present immunohistochemical analysis. The most rep-
resentative and vital tumour area was selected and marked
on H&E (haematoxylin and eosin)-stained slides. There
was no restriction to the tumour periphery or tumour
centre. For the construction, we used a manual tissue-
array instrument (Beecher Instruments, Silver Spring,
MD, USA). At least three and a maximal six 0.6-mm-thick
tissue cores were taken from each tumour. Each block
contained normal mucosa from resection margins of
diverticulosis specimen and cores with liver tissue for
tissue microarray (TMA) orientation.
Immunohistochemistry of TMA
Immunohistochemistry of p62, LC3, Beclin-1 and ULK1
was performed on 5-μm-thick paraffin sections. Antigen
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retrieval was carried out with a hot water bath at pH 9.0
(p62) for 20 min or pH 6.0 (Beclin-1) for 30 min in a
hot water bath (95 °C). Sections were incubated with
p62 antibodies (1:1000 dilution) or Beclin-1 antibodies
(1:400) for 30 min at room temperature. Antibody re-
trieval for LC3B was carried out with hot water bath
(95 °C) for 20 min at pH 9.0. Detection was performed
with the Zytomed Polymer Kit (Zytomed Systems,
Berlin, Germany). The monoclonal p62 antibody (clone
D3, sc-28359) purchased from Santa Cruz Biotechnology
(Heidelberg, Germany) is raised against amino acids
151–440 of SQMSTM1/p62 of human origin. The rabbit
polyclonal Beclin-1 antibody (ab55878) was purchased
from Abcam (Cambridge, UK). The LC3B rabbit poly-
clonal antibody was purchased from Cell Signalling Tech-
nology (Danvers, MA, USA) and was raised against the
clone D11. Antigen retrieval for ULK1 was carried with a
hot water bath (98 °C) at pH 9.0. Sections were incubated
with the monoclonal ULK1 antibody (1:400) for 15 min
and detection was performed with Envision™. The ULK1
antibody was purchased from Abcam, Cambridge, UK. In
order the check the specificity of the used antibodies
(Beclin-1, p62, LC3B), we conducted additional cell cul-
ture experiments and were able to demonstrate specificity
of the antibodies after treatment with chloroquine. We
performed cell culture experiments with HepG2 cells
treated with chloroquine in a final concentration of
50 μmol for 0 and 24 h. The enclosed figures show no or
weak immunoreactivity for LC3, Beclin-1 and p62 but
strong reactivity after 24 h treatment (see Additional
files 1 and 2: Fig. S1 and Table S1). This indicates at
least in cell culture specificity for the target antigen.
KRAS mutation analysis
Mutational analysis was previously performed by our
group [21]. In short, exon 1 of KRAS, harbouring co-
dons 12 and 13, was amplified by polymerase chain reac-
tion (PCR) followed by direct sequencing.
Statistical analysis
Semiquantitative ULK1, p62 and Beclin-1 staining were
assessed by two of the authors (CA, KJS) and LC3 stain-
ing by two of the authors (CA, KJS) in a blind-trial fash-
ion without knowledge of the clinical outcome. In cases
with striking discordance, slides were re-evaluated by
KJS and a final decision was made. All data were statisti-
cally analysed using SPSS Statistics Version 20. Relation-
ships between ordinal parameters were investigated
using two-tailed chi-square analysis. The Kaplan-Meier
method was used to estimate overall survival (OS), and
any differences in the survival curves were compared by
log-rank test. For multivariate analysis, Cox regression
was used. For both tests, a p value of 0.05 or less was
considered to be of statistical significance. Overall, 95 %
confidence intervals were used throughout this study.
Results
Immunohistochemical analysis of LC3, p62, Beclin-1
and ULK1
p62 and Beclin-1 immunohistochemistry of the tumour
tissue revealed varying nuclear and cytoplasmic immuno-
staining. p62 and Beclin-1 immunohistochemistry demon-
strated diffuse cytoplasmic staining and occasionally
dot-like staining in the tumour specimens. Frequent
detection of dot-like p62 and Beclin-1 staining was
obstructed by the overwhelming presence of a diffuse
staining pattern. Adjacent liver tissue on the same slide
exhibited a dot-like p62 staining pattern. LC3 immuno-
staining showed a typical cytoplasmic dot-like staining
and no diffuse cytoplasmic staining was observed. ULK1
staining showed a solely cytoplasmic and membranous
staining pattern. Representative staining examples of p62,
Beclin-1, LC3 and ULK1 are shown in Figs. 1, 2, 3 and 4.
Normal colon mucosal tissue from diverticulosis speci-
men was embedded in every single multi-tissue tumour
block. Non-tumorous colonic epithelium lacked p62 and
LC3B immunostaining. Macrophages and other stromal
cells exhibited a weak to moderate p62 positivity. Neuronal
cells demonstrated a moderate to strong LC3B immunoex-
pression. A missing to weak Beclin-1 immunostaining was
noticed in normal mucosal epithelial tissue whereas nor-
mal colonic epithelium lacked any ULK1 immunostaining.
A weak to moderate ULK1 staining of blood vessel walls
can be used as internal ULK1 staining control. Staining re-
sults of non-tumorous colonic mucosa are shown in Fig. 5.
We next performed separate analyses of the different
autophagy markers with respect to intensity and staining
localization.
Cytoplasmic p62 immunostaining
We classified tumour cytoplasmic staining as positive
(+1) if one or more cores exhibited positive cytoplasmic
p62 immunostaining regardless of staining intensity, or
negative (0). Data for cytoplasmic p62 staining was avail-
able in 126 cases; in one case, all cores were lost from
the slide. A total of 15 (11.9 %) tumours were classified
as cytoplasmic p62 negative and 111 (88.1 %) were clas-
sified as cytoplasmic p62 positive. Statistical analysis re-
vealed a trend towards cytoplasmic p62 negativity in
patients with lymphonodal metastasis (p = 0.072; Table 1).
Statistical chi-square analysis did not show correlations
between p62/sequestosome1 and histological grading,
tumour stage or distant metastasis.
Nuclear p62 immunostaining
Data for nuclear p62 immunostaining was available
for 125 patients. p62 nuclear staining was classified as
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negative (no nuclear or weak nuclear staining), low (mod-
erate nuclear staining) or high (strong nuclear staining),
independent of the amount of stained nuclei. A total of 45
(35.4 %) cases were classified as negative nuclear p62, 61
(48 %) as low nuclear p62 and 19 (15 %) as high nuclear
expression. Chi-square analysis revealed no association of
nuclear p62 staining with clinicopathological parameters.
There was no association with OS (Kaplan-Meier analysis).
Cytoplasmic Beclin-1 immunostaining
We classified Beclin-1 cytoplasmic staining of tumours
as positive (+) if one or more cores exhibited a moderate
or strong cytoplasmic Beclin-1 immunostaining regard-
less of amount of stained tumour cells or negative (0).
Data for cytoplasmic Beclin-1 staining was available for
116 cases. Cores were lost on the slides for 11 cases. A
total of 65 (56 %) were classified as negative and 51
(44 %) as positive. Statistical analysis showed no correl-
ation with the clinicopathological parameters (histo-
logical grading, tumour stage, lymph node metastases
status, distant metastases, or KRAS mutational status).
Nuclear Beclin-1 immunostaining
Beclin-1 nuclear staining was classified as negative (0)
and positive (+). Tumours missing nuclear Beclin-1 im-
munostaining or showing a weak nuclear Beclin-1 stain-
ing were classified as negative (0). Tumours showing a
moderate or strong nuclear immunostaining (regardless
of the amount of stained tumour cell nuclei) were classi-
fied as positive (+). Among the 116 total cases, 64
(55.2 %) were classified as negative and 52 (44.8 %) as
positive. No statistical correlation was detected between
nuclear Beclin-1 expression and the clinicopathological
data (chi-square analysis).
LC3 immunostaining
LC3 staining revealed a typical dot-like staining pattern
in the cytoplasm of tumour cells. Tumours with no LC3
staining were classified as negative, and tumours demon-
strating a dot-like staining, regardless of the amount of
stained cells, were classified as positive. Nerves showed
positive staining for LC3 and thus served as an internal
staining control (Fig. 3). Among the total 128 cases
Fig. 1 p62 immunohistochemistry. Examples of p62 immunostaining in colorectal cancers. The upper row shows three tumours with strong
cytoplasmic immunostaining and the lower row demonstrates three tumours with negative p62 staining (×400 magnification). Note the positively
stained of stromal cells/macrophages, which can be used as internal controls
Fig. 2 Beclin-1 immunhistochemistry. Examples of Beclin-1 immunostaining in colorectal cancers. On the left, there is a cancer without any Beclin-1
immunostaining. In the middle, there is a cancer with prominent cytoplasmic Beclin-1 immunostaining whereas on the right a colorectal cancer exhibits
a mainly nuclear Beclin-1 expression (×400 magnification)
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available for LC3 analysis, 88 (68.8 %) were classified as
LC3 negative and 35 (27.3 %) as LC3 positive. No statis-
tical correlation was detected between LC3 and p62/
Beclin-1 expression. LC3 positivity was significantly as-
sociated with a poor differentiation grade (p = 0.016; chi-
square analysis).
ULK1 immunostaining
Tumour cell nuclei lacked ULK1 immunostaining. Cases
with moderate or strong cytoplasmic staining occasion-
ally also demonstrated a significant membranous stain-
ing pattern. Tumour with missing or weak staining were
classified as negative (0), and tumours with moderate or
strong cytoplasmic and/or membranous staining were
classified as positive (+). No statistical correlation was
detected between ULK1 staining and survival. ULK1
positive staining was significantly associated with the
presence of lymph node metastasis (p = 0.037, chi-square
analysis). There was no association with the remaining
clinicopathological parameters (data not shown).
p62, LC3, Beclin-1 and ULK1 expression and KRAS
mutational status
KRAS mutation analysis of the present cohort was per-
formed in a previous study [21]; thus, the KRAS status of
most patients (n = 124) was known. Cytoplasmic/nuclear
p62 expression was not related to KRAS mutational status
(p = 0.607). Furthermore, neither cytoplasmic nor nuclear
Beclin-1 expression was related to KRAS mutational sta-
tus. LC3 and ULK1 expression was also not related to
KRAS mutational status.
Prognostic relevance of p62, Beclin-1, LC3 and ULK1
immunoexpression with respect to KRAS mutational
status
Patients with cytoplasmic p62-negative CRC exhibited a
significantly shortened OS (p = 0.043, Fig. 6). Histological
grading, lymph node metastases, tumour stage and distant
metastases were also significantly correlated with patient
outcome (Table 2). Nuclear p62 immunostaining did not
show a statistical significant association with OS.
Cytoplasmic p62 immunostaining and the relevant
clinicopathological parameters were subjected to multi-
variate analyses. Only distant metastases qualified as an
independent prognostic marker of OS (p = 0.004, Table 3).
In Kaplan-Meier survival analysis, there was a trend
demonstrating the negative prognostic effect of decreased
p62 expression solely in the subgroup of CRC with KRAS
mutation (p= 0.062, log-rank test) in comparison to the CRC
subgroup with wildtype KRAS (p= 0.457, log-rank test).
In the complete cohort, neither cytoplasmic nor
nuclear Beclin-1 expression was associated with OS.
When stratified into wildtype and mutated KRAS, posi-
tive nuclear (but not cytoplasmic) Beclin-1 expression
was significantly associated with an unfavourable OS
solely in the mutated KRAS CRC group (p = 0.010;
Fig. 3 LC3 immunohistochemistry. On the left side, there is a cancer without any dot-like LC3 immunostaining. Notice the positively stained nerve,
which can be considered as a positive internal control, since nerve fibers are constantly LC3 positive. On the right side, there is a CRC with a
strong and characteristic dot-like LC3 immunostaining. A diffuse cytoplasmic staining was not noticed (×400 magnification)
Fig. 4 ULK1 immunhistochemistry. On the left, there is a picture of a cancer with strong cytoplasmic immunostaining. In the middle, there is a
cancer with barely seen faint ULK1 staining, classified as negative. On the right side, missing staining in normal mucosa is demonstrated. Note the
positivity in small blood vessels as an internal control (×400 magnification)
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Fig. 5 Autophagy-related proteins in normal colonic epithelial tissue. In the upper left, the picture shows normal crypts lacking Beclin-1 immunoexpression.
In the upper right, negative p62 staining can be seen in normal colonic crypts. Notice the positive staining in macrophages. The lower left picture
demonstrates lack of LC3B expression in crypts. Notice the moderate LC3B positivity in nerve cells. The lower right light micrograph shows a lack of
ULK1 staining in normal crypts (×400 magnification)
Table 1 Immunostaining for cytoplasmic p62, nuclear Beclin-1 and LC3 expression
Cytoplasmic p62 expression Nuclear Beclin-1 expression LC3 expression
Negative Positive p value Negative Positive p value Negative Positive p value
Histological grading 0.920 0.746 0.016
1 3 (10 %) 27 (90 %) 15 (53.6 %) 13 (46.4 %) 25 (83.3 %) 5 (16.7 %)
2 9 (12.6 %) 61 (87.1 %) 37 (53.6 %) 32 (46.4 %) 50 (74.6 %) 17 (25.4 %)
3 3 (11.5 %) 23 (88.5 %) 12 (63.2 %) 7 (36.8 %) 13 (50 %) 13 (50 %)
Tumour stage 0.491 0.373 0.124
pT1 0 (0 %) 3 (100 %) 1 (33.3 %) 2 (66.6 %) 2 (66.7 %) 1 (33.3 %)
pT2 0 (0 %) 12 (100 %) 4 (36.4 %) 7 (63.6 %) 10 (83.3 %) 2 (16.7 %)
pT3 11 (14.3 %) 66 (85.7 %) 43 (60.6 %) 28 (48.3 %) 57 (76 %) 18 (24 %)
pT4 4 (12.5 %) 28 (87.5 %) 15 (51.7 %) 14 (48.3 %) 17 (54.8 %) 14 (45.2 %)
Lymph node metastases status 0.072 0.500 0.272
pN0 4 (6.9 %) 54 (93.1 %) 31 (55.4 %) 25 (44.6 %) 42 (75 %) 14 (25 %)
pN+ 11 (17.2 %) 53 (82.8 %) 30 (53.6 %) 26 (46.4 %) 43 (68.3 %) 20 (31.7 %)
Distant metastasis 0.189 0.118 0.027
pM0 9 (9.6 %) 85 (90.4 %) 52 (57.8 %) 38 (42.2 %) 71 (77.2 %) 21 (22.8 %)
pM+ 5 (17.9 %) 23 (82.1 %) 9 (40.9 %) 12 (59.1 %) 15 (55.6 %) 12 (44.4 %)
KRAS status 0.607 0.297 0.242
KRAS wildtype 11 (12.2 %) 79 (87.8 %) 46 (57.5 %) 34 (42.5 %) 66 (74.2 %) 23 (25.8 %)
KRAS mutated 4 (11.8 %) 30 (88.2 %) 17 (50 %) 17 (50 %) 21 (65.6 %) 11 (34.4 %)
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log-rank test; Fig. 7), but not in the wildtype KRAS CRC
group (figure not shown).
To evaluate LC3 immunostaining, Kaplan-Meier sur-
vival analysis was performed on the complete cohort
(KRAS wildtype and KRAS mutated). LC3 expression did
not show significant association with OS in the complete
cohort; however, a statistical trend was observed (p =
0.063, Fig. 8). When stratified into wildtype and mutated
KRAS groups, positive LC3 dot-like staining was signifi-
cantly associated with decreased OS in the mutated KRAS
CRC group (log-rank test: p = 0.023, Fig. 9) but not in the
wildtype KRAS CRC group (p = 0.23).
ULK1 expression was not associated with survival
neither in the complete cohort nor in the mutated-
type CRC.
Prognostic relevance of p62 and Beclin-1 immunoexpression
with respect to UICC stage
Survival analysis was performed in early stage UICC I/II
CRCs and advanced stage UICC III/IV CRCs. Neither
nuclear nor cytoplasmic p62 immunostaining showed a
statistically significant association with OS in both sub-
groups (data not shown). Positive nuclear (but not cyto-
plasmic) Beclin-1 expression was significantly associated
with an unfavourable OS solely in the advanced UICC
III/IV CRCs (p = 0.011; log-rank test; Fig. 10) but not in
early stage UICC I/II CRCs (figure not shown). All
patients in this cohort with UICC III/IV CRCs received
5-FU-based chemotherapy.
Discussion
Autophagy is a cellular pathway that regulates transpor-
tation of cytoplasmic macromolecules and organelles to
Fig. 6 Kaplan-Meier survival plot of 126 colorectal cancers (KRAS wildtype and KRAS mutated) in relation to p62 immunostaining intensity. p62-
negative CRC revealed a significantly decreased OS (log-rank test: p = 0.043)
Table 2 Univariate analysis (Kaplan-Meier, log-rank test) for
prognostic significance of p62, histological grading, lymph node
and distant metastases and tumour stage in relation to tumour-
specific overall survival in the complete cohort
Parameter p value
Cytoplasmic p62 (negative/positive) 0.043*
Cytoplasmic Beclin-1 expression (positive/negative) 0.464
Nuclear Beclin-1 expression (positive/negative) 0.106
Histological grading (G1-G3) 0.032*
Lymph node metastases (pN0 vs pN+) <0.001*
Tumour stage (pT1-4) <0.001*
Distant metastases (M0 vs M1) <0.001*
*Statistically signifcant
Table 3 Results of multivariate analysis (Cox regression) to
determine the independent prognostic value of different
variables in relation to tumour-specific overall survival in the
complete cohort
Covariate Relative risk 95 % CI p value
p62 0.764 NS 0.619
Histological grading 1.239 NS 0.392
Lymph node metastases 0.794 NS 0.510
Tumour stage 1.647 NS 0.141
Distant metastases 3.176 1.453-6.940 0.004
NS statistically not significant
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lysosomes for degradation [22] and ensures protein and
organelle homeostasis [1, 23]. Cancer cells have a high
demand for energy equivalents and specific metabolites,
and these resources can be provided by autophagy.
Interestingly, autophagy processes in cancer may show
both tumour-promoting and tumour-suppressing effects
depending on many factors, such as tissue type, tumour
stage and the type of oncogenic mutations involved in
the different tumour types [2, 22]. Thus, it is not surpris-
ing that immunohistochemical evaluation of autophagy-
related markers has revealed different results according
to prognosis. However, autophagy inhibitors may serve
Fig. 7 Kaplan-Meier survival plot of 34 KRAS-mutated colorectal cancers in relation to nuclear Beclin-1 immunoexpression. Strong nuclear Beclin-1
expression was significantly associated with decreased OS survival (log-rank test: p = 0.010)
Fig. 8 Kaplan-Meier survival plot of 123 colorectal cancers (KRAS wildtype and KRAS mutated) in relation to dot-like LC3 immunostaining intensity.
LC3 expression lacked a significant association with OS; however, there was a statistical trend of LC3 expression being associated with decreased
OS (log-rank test: p = 0.063)
Schmitz et al. World Journal of Surgical Oncology  (2016) 14:189 Page 8 of 13
as a potential therapeutic intervention in some cancers,
and thus autophagy may become a clinically relevant
focus in cancer diagnosis and therapy.
In this study, we performed immunohistochemically
analysis of the autophagy-related markers p62, LC3,
Beclin-1 and ULK1 in a cohort of CRCs. We acknowledge
that measurement of the autophagy flux is challenging,
since autophagy flux is a dynamic, multiple-stage process,
including autophagosome formation, maturation and fu-
sion with lysosomes as well as breakdown and release of
macromolecules back to the cytosol. Thus, the accu-
mulation of autophagosomes as roughly measured by
Fig. 9 Kaplan-Meier survival plot of 32 KRAS-mutated colorectal cancers in relation to dot-like LC3 immunoexpression. LC3 expression was significantly
associated with decreased OS survival (log-rank test: p = 0.023)
Fig. 10 Kaplan-Meier survival plot of 62 colorectal cancers with advanced stage UICC III/IV (all treated with 5-FU-based chemotherapy) in relation
to nuclear Beclin-1 immunoexpression. In this subgroup, strong Beclin-1 expression was significantly associated with decreased OS survival (log-
rank test: p = 0.011)
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immunohistochemistry could indicate either autophagic
activation or a blockage of downstream actions, such as
inefficient fusion or decreased lysosomal degradation [1].
However, immunohistochemical analysis of autophagy-
related markers such as LC3 offers the opportunity to
generate a temporary picture of the amount of autophago-
some formation in tumour tissue at a specific point of
time in a certain clinical setting [7].
Autophagy-related markers have been a subject of recent
immunohistochemical studies in gastrointestinal adenocar-
cinomas (cholangiocarcinoma, pancreatic adenocarcinoma,
oesophageal adenocarcinoma, gastric adenocarcinoma).
Table 4 summarizes previously published study results and
gives an overview about the expression of autophagy
markers in cancer tissue and their potential clinical rele-
vance in gastrointestinal carcinomas other than CRC.
The prognostic relevance of LC3 expression in CRC
has been addressed in only a few studies so far. One
study demonstrated a prognostic impact of LC3 expres-
sion in CRC, while another failed to demonstrate prog-
nostic relevance of LC3 expression [24, 25]. Our study
showed a statistical trend demonstrating reduced OS in
CRC patients with LC3-positive CRC.
Only few studies on p62 and colorectal cancer have
been published thus far. In a recent study on 178 colon
carcinomas treated with adjuvant 5-FU, Beclin-1 overex-
pression (but not p62) was significantly associated with
worse OS [25]. Another study was performed on p62 ex-
pression in various gastrointestinal cancers; however,
this study included only 45 colon cancers and thus the
results may not be reliable [26]. Immunohistochemical
analysis of p62 expression has been examined in various
other human malignancies with differing results. High
cytoplasmic p62 expression and LC3 overexpression
were associated with an unfavourable prognosis in oral
squamous cell carcinoma [27, 28]. High cytoplasmic p62
expression was associated with decreased OS in triple
negative breast cancer [29] and lung adenocarcinoma
[30]. In these studies, increased cytoplasmic p62 expres-
sion was accompanied by an unfavourable course of can-
cer disease. However, in the present study, cytoplasmic
negativity was significantly associated with a reduced
cancer-specific OS, but did not qualify as an independent
prognostic marker in multivariate survival analysis. At first
glance, our results seem surprising, since the previously
published studies revealed increased and not decreased
p62 expression as a negative prognostic marker. On the
other hand, there are also diverging reports about the po-
tential prognostic relevance of p62 in human cancer [27].
p62 is a protein, which is embedded in multiple pathways
and can exert manifold functions. It is well known that
p62 may act as an adaptor protein that transports ubiqui-
tinated protein aggregates to autophagosomes via its
association with LC3B. In addition, p62 influences the
oxidative stress response, which is regulated by the
Keap1-Nrf2 system. However, given the fact that negative
(and not increased) p62 cytoplasmic expression is associ-
ated with worse OS in our study, there has to be another
explanation for this rather surprising finding. Indeed, at
least two p62-related mechanisms may explain the aggres-
sive course of p62-negative colorectal cancer:
1) p62 may also act as a tumour suppressor since it
is capable of inducing autophagic degradation of reg-
ulators of the Wnt signalling pathway [31]. It is
tempting to speculate that deficiency of p62 might upreg-
ulate this oncogenic pathway resulting in increased bio-
logical aggressiveness.
2) Recent studies demonstrated that the lack of cdk1-
mediated phosphorylation of p62 leads to enhanced cell
proliferation and tumorigenesis in response to RAS-
induced transformation [32]. A decrease in p62 protein
thus may lead to a faster exit from mitosis, which trans-
lates into enhanced cell proliferation. These mechanisms
might provide a rationale explanation for the worse prog-
nosis of p62-negative CRC. In addition, this finding might
also explain the significant prognostic impact in the KRAS-
mutated subgroup due to increased RAS-signalling.
In fact, results of a very recent study on 116 oesophageal
adenocarcinomas are in line with our results. The immu-
nohistochemical study of Adams et al. established miss-
ing/low (and not increased) p62 immunostaining as a
predictor of worse prognosis in this cohort [33].
To complicate the evaluation of autophagy-related pro-
teins, both cytoplasmic and nuclear staining has been de-
scribed in previous studies. Although autophagy-related
markers are thought to exert their effects mainly in the
cytoplasm, these markers may be localized both in the
cytoplasmic compartment as well as in the nuclear com-
partment [34]. Indeed, in a previous study on CRCs,
nearly half of the cancers exhibited a significant nuclear
Beclin-1 staining pattern [16].
Autophagy can exert both tumour-suppressive and
tumour-promoting effects in human malignancies [22].
Recent studies showed that activation of oncogenic RAS,
which is capable of inducing tumour growth, is sufficient
to upregulate basal autophagy [35]. RAS mutation is a
frequent and early tumour-promoting event in CRC. We
analysed p62 expression in KRAS wildtype and KRAS-
mutated-type CRC in this study and investigated the
prognostic power of p62 expression. p62 expression was
not correlated to RAS mutational status, but the prog-
nostic power of p62 was lost in the wildtype KRAS sub-
group, whereas it was observed as a trend (p = 0.062) in
the KRAS-mutated subgroup. However, these results
must be interpreted with caution. Cytoplasmic and nu-
clear Beclin-1 expression failed to show prognostic
power in the complete cohort and especially in the wild-
type KRAS CRC subgroup. However, in the mutated
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Table 4 Literature review on immunohistochemical expression of autophagy-related proteins in gastrointestinal adenocarcinoma other than colorectal carcinoma
Tumour type Number p62 Beclin-1 LC3B ULK1 Clinical relevance References
Gastric
adenocarcinoma
61 Positive nuclear 57 %
Positive cytoplasmic 61 %
– – – p62: High p62 expression associated with low differentiation grade
but less lymph node metastasis
[26]
510 Positive 49.2 % Positive 24.7 % Positive 15.5 % – Autophagy (defined as at least two of three markers positive) was
associated with poor survival
[42]
75 – Positive 70.6 % – – No survival analysis performed. Increased Beclin-1 expression in
well differentiated gastric cancer compared to normal mucosa.




18 Positive nuclear 78 %
Positive cytoplasmic 56 %
– – – p62: none [26]
73 Positive 47.9 % Positive 83.3 % Beclin-1 overexpression was associated with poor prognosis [44]
63 Positive 22.2 % Beclin-1 overexpression was associated with favourable prognosis [45]
Intrahepatic
cholangiocarcinoma
108 – Strong expression 24.1 %,
48,1 % moderate and 27.8 %
weak/negative expression
– – Low Beclin-1 expression was associated with worse OS and DFS.




116 – – High p62 81 %
High LC3B 83.6 %
















KRAS CRC subgroup, increased nuclear Beclin-1 ex-
pression was significantly associated with decreased OS.
The altered prognostic effect of autophagy-related
markers in KRAS-mutated CRC represents a novel finding
of our study. Interestingly, similar to Beclin-1, LC3-
positive CRC with mutated KRAS demonstrated a signifi-
cantly reduced OS but not in the KRAS wildtype CRC
group, strengthening this finding. Thus there seems to be
an alteration of the autophagy flux in the setting of KRAS
mutation. A larger sample size of this subgroup with
RAS-mutated cancers should be examined to confirm
these results.
A previous study on CRCs reported the presence of
nuclear Beclin-1 staining; however, the nuclear staining
pattern lacked any prognostic relevance [16]. Neverthe-
less, the results of the present study need to be repro-
duced in larger cohorts. It is particularly important to
conduct additional studies of autophagy-related markers
with a focus on the cellular localizations of the proteins.
Taking into account the results of previous studies on
the prognostic relevance of p62 expression in CRC,
why both underexpression and overexpression of this
autophagy-related protein were demonstrated to influ-
ence survival in CRC as well as in other malignancies
remains unclear. This question cannot be answered by the
present study, since this study remains descriptive and
lacks functional investigations.
ULK1 expression has been addressed in only one study
on CRC so far [36]. Zou et al. were able to demonstrate
that increased expression levels of ULK1 predicted poor
prognosis in CRC. However, in our study with a smaller
number of patients, we were not able to confirm these
results. Nevertheless, in our study, increased ULK1
expression was significantly associated with the presence
of lymph node metastasis. It has to be critically empha-
sized that in the study by Zhou et al., level of signifi-
cance was rather low.
Analysis of autophagy-related proteins in human ma-
lignancies represents a valuable area of research due to
the potential future therapeutic relevance.
Recent in vitro and in vivo studies in preclinical
models suggested that modulation of autophagy can be
used as a therapeutic modality to enhance the efficacy of
conventional therapies, including chemotherapy and ra-
diation therapy [37–40].
Clinical studies with autophagy inhibition are already
being conducted [41] with most of the studies using
hydroxychloroquine as an autophagy inhibitor. However,
autophagy inhibition in human malignancies remains a
topic of clinical studies and is not yet part of established
therapeutic approaches. Our data show that p62, LC3
and Beclin-1 represent promising novel therapeutic
targets especially in the subgroup of KRAS-mutated
colorectal cancer patients.
Conclusions
Our study showed that decreased cytoplasmic p62 ex-
pression was significantly associated with an unfavour-
able tumour-specific OS, especially in the subgroup of
KRAS-mutated CRCs. Nuclear Beclin-1 and dot-like
LC3 expression were also associated with decreased OS
solely in the mutated KRAS CRC subgroup. ULK1
expression completely lacked prognostic relevance. Thus
p62, Beclin-1 and LC3 represent promising markers of
novel targeted therapies, especially in the clinically
relevant group of advanced CRCs treated by chemother-
apy and prognostic unfavourable KRAS-mutated CRCs.
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